LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

Abstract

Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 （DLX6-AS1） is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (HR = 2.30, 95% CI: 1.70–3.09, P < 0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P < 0.01), tumor size (P < 0.01), lymph node metastasis (P < 0.01), and distant metastasis (P < 0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

GNG4 Promotes Tumor Progression in Colorectal Cancer

“…Colorectal cancer is a major neoplasm of the digestive tract, which has a high morbidity and mortality rate in China [1]. In recent years, with the change in environment and living habits, the incidence of colorectal cancer has seen a significant upward trend.…”

FGF8–FGFR1 signaling regulates human GnRH neuron differentiation in a time- and dose-dependent manner

“…Two transcripts, DLX6 antisense RNA 1 ( DLX6-AS1 ) and protocadherin 8 ( PCDH8 ), fulfilled these criteria. DLX6-AS1 represents a long non-coding RNA that has a predictive value in various cancers ( Tian et al, 2020 ). PCDH8 , in turn, encodes a transmembrane adhesion and signaling molecule that acts as a tumor suppressor ( Yu et al, 2020 ).…”

LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis

“…Accumulating studies have shown that lncRNAs were abnormally expressed in various cancers, and function as oncogene or tumor suppressor based on these expression level, participate in the initiation and progression of cancer. Previous meta-analyses have indicated that DLX6-AS1 [ 40 ], PVT1 [ 41 ], SNHG15 [ 22 ] and GHET1 [ 24 ] are related to the clinicopathological features and prognosis of various cancers. These evidences indicated that lncRNA may be a specific prognostic biomarker and therapeutic target for cancer.…”